Hanmi Pharmaceutical announced on Oct. 23 that it will participate in the pharmaceutical exhibition Convention on Pharmaceutical Ingredients (CPHI) Worldwide 2023 to be held in Barcelona, Spain, from Oct. 24 to 26, local time.
Held annually in major European countries, CPHI Worldwide is the world’s largest pharmaceutical and bio exhibition. This year, it is anticipated that over 45,000 participants from more than 2,500 pharmaceutical and bio companies in 170 countries will attend.
At this event, Hanmi Pharmaceutical, which has set up an exclusive booth, plans to introduce its self-developed blockbuster products such as Rosuzet, Amozaltan, and Esomezol. Additionally, its will be showcasing its innovative drug pipelines in operation in the areas of metabolic diseases such as obesity, oncology, and rare diseases, totaling over 30 in number.
Alongside this, it intends to promote the state-of-the-art large-scale manufacturing facility at the Pyeongtaek Bioplant (with a maximum culture tank size of 12,500 liters) and the specialized personnel and systems capable of operating it. It is actively planning to engage in “Contract Development and Manufacturing (CDMO)” order activities.
A representative from Hanmi Pharmaceutical commented, “With our unparalleled R&D capabilities and differentiated competitive products, we aim to solidify our footing on the global stage. We also plan to proactively promote the manufacturing capabilities of our Pyeongtaek Bioplant, which meets global standards, to potential clients.”